Jubilant Pharmova Reports 49% Surge in Profit After Tax to Rs 103 Crore
Jubilant Pharmova, a leading pharmaceutical company, has reported a significant 49% increase in profit after tax (PAT) to Rs 103 crore for the first quarter ended June 30, 2025. This marks a robust performance, driven by consistent revenue growth across all business units.
Jubilant PharmovaProfit After TaxPharmaceuticalsRevenue GrowthBusiness UnitsReal Estate PuneJul 29, 2025
The company said the reported PAT in Q1 of FY25 stood at Rs 482 crore due to one-time net exceptional income of Rs 396 crore. Revenue from operations rose to Rs 1,901 crore in the April-June quarter as compared with Rs 1,732 crore in the year-ago period, Jubilant Pharmova said in a regulatory filing.
It is heartening to note that we delivered solid revenue growth across all of our business units, and we expect this growth momentum to grow stronger as we move forward, Jubilant Pharmova Chairman Shyam S Bhartia said. Jubilant Pharmova shares were trading 1.88 per cent down at Rs 1,151.70 apiece on BSE.
Jubilant Pharmova, a leading player in the pharmaceutical and life sciences industries, has been consistently focusing on innovation and strategic partnerships to drive its growth. The company's strong performance in the first quarter of FY25 is a testament to its robust business model and effective operational strategies.
The one-time net exceptional income of Rs 396 crore in the reported PAT for Q1 FY25 is a significant factor contributing to the company's strong financial results. This income primarily stems from the successful execution of several strategic initiatives and the realization of assets that have been under development.
Looking ahead, Jubilant Pharmova is poised to continue its growth trajectory, driven by its focus on research and development, expansion into new markets, and the introduction of innovative products. The company's commitment to quality and customer satisfaction remains unwavering, and it is well-positioned to capitalize on the growing demand for pharmaceutical and life sciences solutions in the global market.
Disclaimer: This story is from the syndicated feed. Nothing has changed except the headline.
Frequently Asked Questions
What was Jubilant Pharmova's profit after tax (PAT) for Q1 FY25?
Jubilant Pharmova reported a profit after tax (PAT) of Rs 103 crore for Q1 FY25, marking a 49% increase from the previous year.
What was the normalized PAT for the June quarter of the last fiscal?
The normalized profit after tax (PAT) for the June quarter of the last fiscal was Rs 69 crore.
What was the reported PAT in Q1 of FY25 and why?
The reported PAT in Q1 of FY25 stood at Rs 482 crore due to a one-time net exceptional income of Rs 396 crore.
How much did the revenue from operations increase in the April-June quarter?
Revenue from operations rose to Rs 1,901 crore in the April-June quarter, up from Rs 1,732 crore in the year-ago period.
What is Jubilant Pharmova's focus for future growth?
Jubilant Pharmova is focusing on innovation, strategic partnerships, expansion into new markets, and the introduction of innovative products to drive future growth.
Related News Articles
MahaRERA's New Portal MahaCRITI Sees Over 2,700 Users, Offers Updates and Training
MahaRERA's new website MahaCRITI has been accessed by over 2,700 users, with 581 promoters updating their information and 8 new projects registered.
Maharashtra Assembly Elections 2024: MVA Finalizes Seat-Sharing, Uddhav Sena to Contest 85 Seats
The Maha Vikas Aghadi (MVA) has reached a consensus on the seat-sharing arrangement for the upcoming Maharashtra Assembly elections. The Congress, NCP (Sharad Pawar faction), and Shiv Sena (UBT) will each contest 85 seats.
Mumbai's Luxury Real Estate Market Heats Up: Urjita Master Buys Worli Apartment for ₹105 Crore
In a significant deal that highlights the robustness of Mumbai's luxury real estate market, Urjita Master has recently acquired a lavish apartment in Worli. The property, which is part of a prestigious project by real estate firm Oberoi Realty, has been s
Amazon Acquires 38 Acres in Ambernath, Mumbai for Rs 450 Crore
In a significant real estate move, Amazon India has finalized the purchase of 38 acres of land in Ambernath, Mumbai, for Rs 450 crore. The deal, which was sealed on November 12, 2024, includes a stamp duty payment of Rs 27 crore. This acquisition undersco
Adani Dharavi Redevelopment Project: Phase 1 Begins, Promising New Hope for Residents
The Adani Dharavi redevelopment project in Mumbai is set to begin its first phase on a 6.4-acre railway land parcel in Matunga West. This ambitious project aims to transform the lives of over a million residents living in the Dharavi slum area by providin
Worli's Property Market Sees Booming Rs 4,862 Crore Ultra-Luxury Deals, Prices Surge 30%
Worli, one of Mumbai's most sought-after luxury real estate hubs, has witnessed a significant surge in property transactions and price appreciation, with ultra-luxury deals totaling Rs 4,862 crore and a 30% increase in prices.